Patients, Imaging Characteristics, and EDR-1m According to Radiopharmaceutical
| Parameter | 68Ga-DOTATOC | 18F-FDOPA | 18F-FDG | 111In-pentetreotide | 123I-MIBG | Comparison |
| Patients (n) | 53 | 15 | 13 | 12 | 10 | χ2: NSD in sex repartition |
| Male | 29 | 6 | 8 | 6 | 3 | |
| Female | 24 | 9 | 5 | 6 | 7 | |
| Age (y) | 56.7 ± 12.3; 58 (30–76) | 60.9 ± 12.1; 61 (29–78) | 64.5 ± 17.0; 66 (37–89) | 62.1 ± 12.6; 63 (38–81) | 51.0 ± 10.2; 53 (30–65) | ANOVA: NSD |
| Body height (m) | 1.70 ± 0.09; 1.71 (1.53–1.96) | 1.70 ± 0.09; 1.67 (1.57–1.83) | 1.66 ± 0.08; 1.69 (1.51–1.77) | 1.70 ± 0.12; 1.72 (1.45–1.86) | 1.68 ± 0.10; 1.69 (1.56–1.83) | ANOVA: NSD |
| Body mass (kg) | 72.4 ± 13.8; 71 (49–105) | 72.3 ± 13.5; 75 (50–91) | 68.4 ± 20.6; 60 (39–120) | 72.7 ± 13.7; 73.5 (54–95) | 73.3 ± 11.0; 76.5 (58–88) | ANOVA: NSD |
| Body mass index (kg⋅m−2) | 24.9 ± 4.27; 24.5 (17.3–37.1) | 24.6 ± 4.27; 24.4 (17.2–34.5) | 24.6 ± 6.01; 23.9 (15.2–38.7) | 25.1 ± 3.79; 24.4 (18.7–30.7) | 26.3 ± 4.03; 25.3 (21.3–33.6) | ANOVA: NSD |
| Injected activity (MBq) | 121 ± 23; 122 (80–170) | 199 ± 48; 198 (97–262) | 176 ± 56; 167 (98–321) | 170 ± 7; 170 (158–179) | 186 ± 5; 184 (176–194) | 68Ga-DOTATOC < all others; KW: P <<0.001 |
| Injected activity per kg body mass (MBq/kg) | 1.72 ± 0.42; 1.77 (0.89–2.80) | 2.74 ± 0.42; 2.83 (1.87–3.27) | 2.59 ± 0.38; 2.51 (2.23–3.81) | 2.41 ± 0.48; 2.30 (1.77–3.29) | 2.58 ± 0.45; 2.43 (2.00–3.27) | 68Ga-DOTATOC < all others; ANOVA: P < 0.001 |
| Interval between injection and EDR-1m measurement (min) | 90 ± 16; 87 (66–126) | 114 ± 14; 117 (86–130) | 112 ± 39; 95 (82–220) | 6.2 ± 3.5; 5 (2–15) | 5.7 ± 2.6; 5 (3–10) | PENT & 123I-MIBG < 68Ga-DOTATOC < 18F-FDOPA & 18F-FDG; KW: P << 0.001 |
| EDR-1m from sternum (μSv/h) | 4.73 ± 1.41; 4.75 (2.10–9.10) | 9.76 ± 3.61; 9.50 (3.92–17.7) | 9.34 ± 3.51; 8.80 (3.50–18.8) | 9.56 ± 0.93; 9.43 (8.50–11.0) | 4.94 ± 0.31; 4.89 (4.45–5.49) | 68Ga-DOTATOC & 123I-MIBG < all others; KW: P << 0.001 |
| EDR-1m from bladder (μSv/h) | 5.04 ± 1.37; 5.10 (2.13–8.20) | 10.2 ± 3.20; 10.1 (4.57–15.8) | 10.5 ± 4.28; 9.50 (3.80–21.2) | 9.21 ± 1.31; 9.30 (5.81–11.2) | 4.41 ± 0.93; 4.68 (2.80–5.65) | 68Ga-DOTATOC & 123I-MIBG < all others; KW: P << 0.001 |
| EDR-1m from sternum per injected MBq (nSv/h/MBq) | 39.4 ± 10.7; 37.7 (21.9–89.7) | 51.7 ± 25.1; 45.5 (25.0–116) | 54.4 ± 13.8; 57.1 (16.5–71.5) | 56.3 ± 4.6; 55.5 (50–64) | 26.6 ± 1.5; 26.5 (23.6–29.5) | 123I-MIBG < 68Ga-DOTATOC & 18F-FDOPA < 18F-FDG & PENT; KW: P << 0.001 |
| EDR-1m from bladder per injected MBq (nSv/h/MBq) | 41.9 ± 10.0; 41.0 (25.4–88.5) | 54.0 ± 23.0; 44.8 (26.1–104) | 60.4 ± 15.5; 62.1 (17.9–82.9) | 54.3 ± 7.3; 56.0 (34.1–62.5) | 23.7 ± 4.9; 25.0 (15.3–29.1) | 123I-MIBG < 68Ga-DOTATOC < 18F-FDOPA & PENT < 18F-FDG; KW: P << 0.001 |
NSD = no significant difference; KW = Kruskal–Wallis test; PENT = 111In-pentetreotide.
Data are mean ± SD, or median followed by range in parentheses.